| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenues | — | — | — | $10.88B+9.2% | $9.96B+13.7% | $8.76B-6.4% | $9.36B+67.9% | $5.58B | — |
| Premiums | $40.26B-12.5% | $46.00B+4.0% | $44.24B+10.8% | $39.92B-3.0% | $41.15B-3.5% | $42.63B+7.3% | $39.71B+10.0% | $36.11B+11.1% | $32.49B |
| Net investment income | $1.05B+7.5% | $973.0M-16.6% | $1.17B+1.0% | $1.16B-25.4% | $1.55B+24.5% | $1.24B-10.5% | $1.39B-6.1% | $1.48B+20.7% | $1.23B |
| TOTAL REVENUES | $274.90B+11.2% | $247.12B+26.6% | $195.26B+8.2% | $180.52B+3.7% | $174.08B+8.5% | $160.40B+4.5% | $153.57B+215.7% | $48.65B+16.4% | $41.81B |
| Pharmacy and other service costs | $214.99B+17.8% | $182.51B+36.4% | $133.80B+7.2% | $124.83B+6.2% | $117.55B+13.6% | $103.48B+6.0% | $97.67B+1937.7% | $4.79B+95.2% | $2.46B |
| Medical costs and other benefit expenses | $34.35B-11.1% | $38.65B+6.5% | $36.29B+12.7% | $32.18B-4.1% | $33.56B+2.6% | $32.71B+6.1% | $30.82B+12.0% | $27.53B+9.0% | $25.26B |
| Selling, general and administrative expenses | $14.62B-1.5% | $14.84B+0.1% | $14.82B+12.5% | $13.17B+1.1% | $13.03B-7.4% | $14.07B+0.1% | $14.05B+17.8% | $11.93B+19.0% | $10.03B |
| Amortization of acquired intangible assets | $1.74B+2.3% | $1.70B-6.4% | $1.82B-3.0% | $1.88B-6.1% | $2.00B+0.8% | $1.98B-32.8% | $2.95B+1154.9% | $235.0M+104.3% | $115.0M |
| TOTAL BENEFITS AND EXPENSES | $265.70B+11.8% | $237.70B+27.3% | $186.73B+8.5% | $172.07B+3.6% | $166.14B+9.1% | $152.25B+4.6% | $145.49B+227.0% | $44.49B+17.5% | $37.86B |
| Income from operations | $9.20B-2.3% | $9.42B+10.3% | $8.54B+1.0% | $8.45B+6.5% | $7.93B-2.7% | $8.15B+0.9% | $8.08B+94.2% | $4.16B+5.5% | $3.94B |
| Interest expense and other | -$1.41B+1.9% | -$1.44B+0.8% | -$1.45B-17.8% | -$1.23B-1.7% | -$1.21B+16.0% | -$1.44B+14.5% | -$1.68B-237.8% | -$498.0M-97.6% | -$252.0M |
| Net gain (loss) on sale of businesses | $13.0M-45.8% | $24.0M+101.6% | -$1.50B-190.2% | $1.66B | $0-100.0% | $4.20B | $0 | $0 | — |
| Net investment losses | -$24.0M+99.1% | -$2.74B-3409.0% | -$78.0M+84.0% | -$487.0M | — | — | — | — | — |
| Income before income taxes | $7.78B+47.7% | $5.27B-4.4% | $5.51B-34.3% | $8.40B+23.8% | $6.78B-37.6% | $10.87B+65.4% | $6.57B+83.5% | $3.58B-0.7% | $3.61B |
| TOTAL INCOME TAXES | $1.49B+0.1% | $1.49B+957.4% | $141.0M-91.3% | $1.61B+18.1% | $1.37B-42.5% | $2.38B+64.1% | $1.45B+55.1% | $935.0M-32.0% | $1.37B |
| Net income | $6.29B+66.4% | $3.78B-29.7% | $5.37B-20.8% | $6.78B+25.2% | $5.42B-36.2% | $8.49B+65.8% | $5.12B+93.5% | $2.65B+18.5% | $2.23B |
| Less: Net income attributable to noncontrolling interests | $331.0M-3.8% | $344.0M+65.4% | $208.0M+166.7% | $78.0M+56.0% | $50.0M+61.3% | $31.0M+93.8% | $16.0M+77.8% | $9.0M+280.0% | -$5.0M |
| SHAREHOLDERS' NET INCOME | $5.96B+73.5% | $3.43B-33.5% | $5.16B-23.0% | $6.70B+25.0% | $5.37B-36.6% | $8.46B+65.7% | $5.10B+93.6% | $2.64B | — |
| Basic (in dollars per share) | $22330000.00+82.3% | $12250000.00-30.3% | $17570000.00-18.9% | $21660000.00+36.5% | $15870000.00-31.5% | $23170000.00+70.6% | $13580000.00+27.0% | $10690000.00+19.8% | $8920000.00 |
| Diluted (in dollars per share) | $22180000.00+83.0% | $12120000.00-30.3% | $17390000.00-18.8% | $21410000.00+36.1% | $15730000.00-31.5% | $22960000.00+70.8% | $13440000.00+27.5% | $10540000.00+20.2% | $8770000.00 |
| Pharmacy revenues | |||||||||
| Revenue from contract with customer | $16.92B+14.4% | $14.79B+17.2% | $12.62B+16.0% | $10.88B-91.0% | $121.41B+12.7% | $107.77B+4.5% | $103.10B+1781.7% | $5.48B+7.2% | $5.11B |
| Fees and other revenues | |||||||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.